Antitumor effect of a WEE1 inhibitor and potentiation of olaparib sensitivity by DNA damage response modulation in triple-negative breast cancer

Dong-Hyeon Ha(Seoul National University), Seock‐Ah Im(Seoul National University)

Scientific Reports

June 18, 2020

10.1038/s41598-020-66018-5

Cited by 82

Related Papers

Palbociclib and Letrozole in Advanced Breast Cancer

|New England Journal of Medicine|2016|2.9k

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

|New England Journal of Medicine|2022|2.5k

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

|The Lancet Oncology|2016|1.8k

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

|The Lancet|2020|1.8k

ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer

|Annals of Oncology|2021|1.4k